Alopecia Areata (AA)

  • It is estimated that alopecia areata affects 700,000 people in the US with moderate to severe at 300,000 people (NIH)
  • The global alopecia treatment market size was estimated at $2.7 billion in 2020 and is projected to reach $4.9 billion by 2028(1)

Graft-vs-Host-Disease (GvHD)/Transplant Rejection

  • Chronic GvHD is on the rise with the increased use of allogeneic hematopoietic stem cell transplantation (HSCT)
  • It is estimated that 10-15% of tissue transplants are rejected, and US 33,000 tissues transplants were performed in the US in 2020
  • The global GvHD treatment market size was estimated at $1.6 billion in 2021 and is projected to reach $2.8 billion by 2027(2)

Vitiligo

  • It is estimated that vitiligo affects 2 million people in the U.S (NIH)
  • The global vitiligo treatment market size was estimated at $1.2 billion in 2018 and is projected to reach $1.9 billion by 2026(3)
  • While JAK inhibitors have demonstrated efficacy in AA, GvHD and vitiligo, black box warnings have dampened enthusiasm for JAK inhibitors. As a result, there remains a significant unmet need for safe and effective therapies

FB-102

  • FB-102 has potentially other autoimmune applications including celiac disease, eosinophilic esophagitis and Type 1 diabetes
  • Forte expects FB-102 to be in the clinic in the second half of 2023